NHL Cyberfamily

Non-Hodgkin's lymphoma support

 

American society of hematology 2014



 

Lymphoma abstracts from the American Society of Hematology (ASH) 2014 convention in San Francisco

ASH abstract home page

Click on any of the categories below to get a list of abstracts on that topic from the 2014 ASH convention. There is an outstanding amount of good information in these abstracts.

Better still, use the search box at the bottom. Fill in any terms of interest and find only abstracts from the 2014 convention that have those terms.

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster I

622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster II

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster I

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster II

623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III

624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I

624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II

624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III

625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster I

625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster II

625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster III

701. Experimental Transplantation: Basic Biology, Engraftment and Disease Activity: Poster I

701. Experimental Transplantation: Basic Biology, Engraftment and Disease Activity: Poster II

701. Experimental Transplantation: Basic Biology, Engraftment and Disease Activity: Poster III

702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster I

702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster II

702. Experimental Transplantation: Immune Function, GVHD and Graft-versus-Tumor Effects: Poster III

703. Adoptive Immunotherapy: Poster I

703. Adoptive Immunotherapy: Poster II

703. Adoptive Immunotherapy: Poster III

721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster I

721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster II

721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster III

722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I

722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II

722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III

723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I

723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster II

723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III

731. Clinical Autologous Transplantation: Results: Poster I

731. Clinical Autologous Transplantation: Results: Poster II

731. Clinical Autologous Transplantation: Results: Poster III

732. Clinical Allogeneic Transplantation: Results: Poster I

732. Clinical Allogeneic Transplantation: Results: Poster II
 

You can also search for any specific word or drug or title from the 2014 abstracts using the search box below. Your search will be limited to the 2014 ASH abstracts.